Headache clinical trials at UCSD
6 in progress, 5 open to eligible people
PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM
open to eligible people ages 22 years and up
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
La Jolla, California and other locations
Combined Transcranial Magnetic Stimulation and Therapy for MTBI Related Headaches
open to eligible people ages 18-65
This study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rTMS) and telehealth based therapy in helping manage mild traumatic brain injury (mTBI) related headaches. The investigators hypothesize that active rTMS combined with telehealth therapy will provide marked reduction in mTBI related headaches and symptoms in comparison to their placebo counterparts.
San Diego, California
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
open to eligible people ages 18-65
This study aims to look at the long term efficacy of using repetitive transcranial magnetic stimulation (rTMS) in relieving Gulf War Illness related headaches and pain.
San Diego, California and other locations
Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
open to eligible people ages 6-17
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
La Jolla, California and other locations
Children and Adolescents With Migraine: Acute Treatment
open to eligible people ages 6-17
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
La Jolla, California and other locations
Inhaled Cannabis for Acute Migraine Treatment
Sorry, currently not accepting new patients, but might later
This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.
La Jolla, California
Our lead scientists for Headache research studies include Nathaniel Schuster, MD Albert Y Leung, MD.
Last updated: